secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001104659-25-005619
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study
--------------------------------------------------------------------------------

- M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.
- WINRS (itch) worsened from 2 at 12 weeks to 8 post-discontinuation, exceeding baseline of 7.
- IGA regressed from 'Almost Clear' at 12 weeks back to 'Moderate', same as baseline.
- Data from first twice-daily dosed subject shows complete reversal of all clinical improvements after stopping QRX003.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/0001104659-25-005619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925005619/tm254263d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-005619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer